ConductScience.org, home
OVCAR-5
API referenceFor AI assistants

Cell line · CVCL_1628

Papers84

1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.

1 to 20 of 84

Download this page as JSON
PaperJournalYearHow we knowRetractedSource
Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas.Mol Oncol2026Its Methods give the RRID and name the linePubMed
A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers.bioRxiv2026Its Methods give the RRID and name the linePubMed
Two-step PEG-based surface functionalization of gold nanoparticles enables specific SERS imaging of EGFR in an ovarian cancer cell model.Mater Today Bio2026Its Methods give the RRID and name the linePubMed
DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment.Cancer Res Commun2026Its Methods give the RRID and name the linePubMed
Enhanced expression of ADAMTS1 in ovarian carcinomas: loss of ADAMTS1 expression instigates cellular reprogramming of extracellular matrix ensuing altered plasticity, augmented migration and attenuated adhesion.
J Biomed Sci2026Its Methods give the RRID and name the linePubMed
Suppression of AKT Activation through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck Cancers.Mol Cancer Ther2026Its Methods give the RRID and name the linePubMed
Platelets induce VISTA expression and modulate the ovarian tumor microenvironment.Platelets2026Its Methods give the RRID and name the linePubMed
KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors.Sci Adv2026Its Methods give the RRID and name the lineRetractedPubMed
Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer.Cancer Res2026Its Methods give the RRID and name the linePubMed
Metabolic Dependency on De Novo Pyrimidine Synthesis Is a Targetable Vulnerability in Platinum-Resistant Ovarian Cancer.Cancer Res2026Its Methods give the RRID and name the linePubMed
DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity.Mol Cancer Ther2026Its Methods give the RRID and name the linePubMed
Epigenetic modulation of BARD1 to enhance anti-VEGF therapy.Cell Rep Med2025Its Methods give the RRID and name the linePubMed
Vertical inhibition of p110α/AKT and N-cadherin enhances treatment efficacy in PIK3CA-aberrated ovarian cancer cells.Mol Oncol2025Its Methods give the RRID and name the linePubMed
Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways.Mol Oncol2025Its Methods give the RRID and name the linePubMed
Plakin Expression in Serous Epithelial Ovarian Cancer Has the Potential to Impede Metastatic Spread and Epithelial-Mesenchymal Transition: A Comparative Expression Analysis of Immunohistochemical and In Silico Datasets.
Cancers (Basel)2024Its Methods give the RRID and name the linePubMed
Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor.SLAS Discov2024Its Methods give the RRID and name the linePubMed
HTS384 NCI60: The Next Phase of the NCI60 Screen.Cancer Res2024Cellosaurus cites it, and its Methods give the RRID and name the linePubMed
A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing.Cancer Res Commun2024Its Methods give the RRID and name the linePubMed
Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation.Nat Commun2023Its Methods give the RRID and name the linePubMed
Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma.Gynecol Oncol2023Its Methods give the RRID and name the linePubMed

cell-lines-2026-11-14-0.1.0

Next page

Sources 4

  • CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
  • PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
  • NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
  • PubMedNLM's terms
Each source's terms
  • CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
  • PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
  • NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
  • PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_1628/papers

API referenceFor AI assistants